Gerhardy A, Scholtysik G, Schaad A, Haltiner R, Hess T
Department of Veterinary Pharmacology, Bern, Switzerland.
Basic Res Cardiol. 1998 Aug;93(4):285-94. doi: 10.1007/s003950050097.
Torsades de Pointes (TdP) is a polymorphic ventricular arrhythmia which can degenerate into ventricular fibrillation. The most typical symptom of TdP is the ECG morphology where QRS complexes seem to rotate around the isoelectric baseline. Bradycardia and delayed repolarization are regarded as pathophysiologic predispositions. For better understanding of the pathophysiology and the evaluation of therapeutic or proarrhythmic potential of drugs, a functional experimental model is needed. In the present study, an experimental model of polymorphic tachyarrhythmias taken as TdP equivalents in isolated guinea pig hearts was developed. The hearts were perfused by the Langendorff technique. Bradycardia was induced by dissection of the sinus node, and prolongation of the QT interval by infusion of two inhibitors of the sodium channel inactivation, veratridine and DPI 201-106. TdP equivalents were triggered reproducibly by application of electrical single stimuli at the end of the T wave. Experiments with different concentrations of the channel active substances alone and in combination, with different perfusion times and mode of electrical stimulation (single pulse versus train stimulation), showed the highest incidence for TdP equivalents by means of an initial 30 min long infusion of 0.5 microM each veratridine and DPI 201-106 in combination with electrical single stimuli. After finishing the infusion with the channel active substances but still with lasting effects from them. TdP equivalents were triggered repeatedly in five of six experiments. The reasons for this increased TdP susceptibility after finishing the infusion are not known. In a separate series of six similarly arranged experiments, the incidence for TdP equivalents could be decreased from 83% to 12.5% (p < 0.001) by increasing the concentration of magnesium in the perfusate from 1.17 to 5.0 mM. With these experiments, the clinically known therapeutic effect of magnesium suppressing TdP could be demonstrated in an in vitro model for the first time. The results suggest that this model could be used as a base for further studies of clinical relevant drugs, especially antiarrhythmic agents, to obtain hints of possible risks of proarrhythmic effects or of suitability for therapeutic use at TdP attacks.
尖端扭转型室性心动过速(TdP)是一种多形性室性心律失常,可恶化为心室颤动。TdP最典型的症状是心电图形态,其中QRS波群似乎围绕等电位基线旋转。心动过缓和复极延迟被视为病理生理易患因素。为了更好地理解病理生理学以及评估药物的治疗或促心律失常潜力,需要一个功能性实验模型。在本研究中,建立了一个在离体豚鼠心脏中作为TdP等效物的多形性快速心律失常实验模型。心脏采用Langendorff技术灌注。通过解剖窦房结诱导心动过缓,并通过输注两种钠通道失活抑制剂藜芦碱和DPI 201-106延长QT间期。在T波结束时施加单个电刺激可重复性地触发TdP等效物。单独和联合使用不同浓度的通道活性物质、不同灌注时间和电刺激模式(单脉冲与串刺激)的实验表明,通过初始30分钟长时间输注0.5微摩尔/升的藜芦碱和DPI 201-106并结合单个电刺激,TdP等效物的发生率最高。在用通道活性物质完成输注后但仍有其持续影响时,在六个实验中的五个实验中反复触发了TdP等效物。输注结束后TdP易感性增加的原因尚不清楚。在另一组六个类似安排的实验中,通过将灌注液中镁的浓度从1.17毫摩尔/升提高到5.0毫摩尔/升,TdP等效物的发生率可从83%降至12.5%(p<0.001)。通过这些实验,首次在体外模型中证明了镁抑制TdP的临床已知治疗效果。结果表明,该模型可作为进一步研究临床相关药物,特别是抗心律失常药物的基础,以获得促心律失常作用可能风险或TdP发作时治疗适用性的线索。